Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348960 | 1.00 | MBOAT4 (0.37) | MBOAT4GBA1GRM2CYP1B1KDM4E | |
| SCHEMBL29965595 | 0.82 | GBA1 (0.33) | MBOAT4GBA1GRM2CYP1B1 | |
| SCHEMBL28685675 | 0.82 | GBA1 (0.33) | MBOAT4GBA1GRM2CYP1B1 | |
| SCHEMBL24553904 | 0.77 | KDM4E (0.34) | CYP1B1KDM4EALDH1A1 | |
| SCHEMBL29683072 | 0.77 | KDM4E (0.34) | CYP1B1KDM4EALDH1A1 | |
| SCHEMBL6643942 | 0.77 | EPHX2 (0.42) | CYP1B1 | |
| SCHEMBL2750287 | 0.73 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL7704422 | 0.72 | CYP1B1 (0.32) | CYP1B1 | |
| SCHEMBL29348902 | 0.71 | GBA1 (0.40) | MBOAT4GBA1GRM2KDM4EALDH1A1 | |
| SCHEMBL29348879 | 0.69 | CYP1A2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | MBOAT4 4342/4885GBA1 1855/4885GRM2 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.